The role of gut microbiota in patients with benign and malignant brain tumors: a pilot studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This pilot study examined the gut microbiota of patients with brain tumors to determine whether benign and malignant tumors are associated with distinct microbial patterns. It compared microbial diversity and composition across benign meningioma, malignant glioma, and healthy control groups. The work builds on prior evidence linking gut microbiota to tumor growth, including malignant gliomas, via the brain-gut axis.
Who was studied?
The study included 32 patients with benign meningioma, 27 patients with malignant glioma, and 41 healthy individuals as controls. This gives a total pilot cohort of 100 participants across the three groups. No further demographic details are provided in the abstract.
What were the most important findings?
Brain tumor patients, both meningioma and glioma groups, showed lower gut microbial diversity than healthy controls, with no significant diversity difference between the two tumor groups. Microbial composition differed significantly between tumor patients and healthy participants. Meningioma patients had increased pathogenic bacteria such as Enterobacteriaceae, while glioma patients showed overrepresentation of carcinogenic bacteria including Fusobacterium and Akkermansia. Both benign and malignant tumor groups lacked SCFA-producing probiotic bacteria.
What are the greatest implications of this study?
The findings suggest that gut microbial alterations, including reduced diversity and loss of SCFA-producing bacteria, are associated with the presence of brain tumors generally, while specific taxa may distinguish benign from malignant disease. The identification of a candidate microbial biomarker panel, including Fusobacterium, Akkermansia, Escherichia/Shigella, Lachnospira, and Agathobacter, points toward potential non-invasive markers for differentiating tumor types. As a pilot study, these results support further investigation into the brain-gut axis as a factor in brain tumor pathology.